Can Psoriasis Be Cured? The Honest Answer, What Remission Really Means, and How to Live Well With the Condition

Of all the questions people ask about psoriasis, this is the one that matters most personally. Not what type they have, not what triggers it, not even how to treat it — but whether there is a finish line. Whether one day, the patches, the itching, the flaking, the self-consciousness, and the daily treatment routine will simply be over. It is the most human question anyone with a chronic condition can ask, and it deserves an honest, thorough, and genuinely useful answer.

The short answer is: no, there is currently no permanent cure for psoriasis. But that single sentence, without context, is more discouraging than the full truth warrants. Because the full truth is that long-term remission — extended periods of near-complete or complete skin clearance — is increasingly achievable for the majority of psoriasis patients. The landscape of what is possible has changed dramatically over the last twenty years, and it continues to change. This article explains what 'no cure' actually means in practice, what remission looks like, every treatment pathway available in India in 2026, emerging research that may eventually change the answer, and — critically — what people with psoriasis can do right now to live as well as possible.

The Honest Answer: No Permanent Cure — But That Is Not the Whole Story

Psoriasis cannot currently be permanently cured. This means that no available treatment — not a cream, not a tablet, not an injection, not surgery, not any dietary protocol — can eliminate psoriasis from the body in a way that means it will never return. The reason for this is rooted in the nature of the disease itself: psoriasis is a systemic autoimmune condition driven by genetic programming and immune system behaviour that cannot, with current science, be permanently reset.

However, 'no permanent cure' does not mean 'no hope', 'no clearance', or 'no control'. It means psoriasis is a chronic condition — one that is managed rather than ended, like type 1 diabetes, rheumatoid arthritis, or asthma. And just as people with type 1 diabetes lead full, healthy lives through effective management, people with psoriasis increasingly achieve skin that is entirely clear for months or years at a time — a state called remission — through the treatments available today.

What 'no cure' means — and what it does not mean:   NO CURE MEANS:                      No treatment permanently ends psoriasis                   Psoriasis can return after treatment is stopped                   Genetic predisposition cannot currently be eliminated   NO CURE DOES NOT MEAN:                   Psoriasis cannot be cleared                   Symptoms cannot be controlled long-term                   Quality of life cannot be excellent                   Research will not eventually find a cure   WHAT IS POSSIBLE: Long-term remission with near-complete or complete skin clearance                   Years of symptom-free living for many patients on appropriate treatment                   Dramatic reduction in flare frequency through lifestyle management

Why Psoriasis Cannot Currently Be Cured: The Biology

To understand why no cure exists — and what a cure would need to achieve — it helps to understand what psoriasis actually is at a biological level. The reason psoriasis resists permanent cure is not a failure of medical effort but a reflection of the profound complexity of the immune system and its genetic programming.

Psoriasis Is Encoded in the Immune System

Psoriasis arises because certain T-lymphocytes (T-cells) in the immune system are genetically primed to overreact to normal skin proteins, triggering the inflammatory cascade that drives plaque formation. This is not a structural abnormality that can be surgically removed, a toxin that can be neutralised, or a single malfunctioning gene that can be switched off. It is a systemic pattern of immune behaviour encoded across more than 80 gene variants, involving multiple cell types and molecular pathways distributed throughout the body.

Every available treatment interrupts this immune process at some point — suppressing the overactive T-cells, blocking the cytokines they produce, or slowing the skin cell proliferation they trigger. But when the treatment is stopped, the underlying genetic programming reasserts itself, the immune dysregulation resumes, and — in most patients — psoriasis returns. This is the fundamental biological reason why current treatments manage rather than cure psoriasis.

Why Remission Occurs Naturally in Some Patients

Some patients — particularly those with guttate psoriasis triggered by a single infectious episode — experience spontaneous remission, sometimes lasting years or decades. In these cases, removing the triggering factor (treating the streptococcal infection, for example) allows the immune dysregulation to settle without ongoing medical treatment. This does not mean the genetic predisposition has gone away; it means the environmental triggers sustaining active disease are no longer present. If those triggers return — another infection, a period of severe stress, a new medication — the condition typically flares again.

Understanding spontaneous remission is instructive for treatment strategy. It shows that psoriasis activity exists on a spectrum driven by both genetic load and environmental burden. Reducing the environmental burden — through stress management, lifestyle modification, trigger avoidance, and gut health optimisation — can shift the balance toward remission even in patients who continue to carry their genetic predisposition.

What a Cure Would Need to Do

A genuine cure for psoriasis would need to permanently reprogram the immune system — either eliminating the self-reactive T-cell populations that drive the condition, correcting the gene variants that make them overreactive, or inducing a state of permanent immune tolerance in which the immune system no longer misidentifies skin proteins as threats. None of the currently available treatments achieve any of these goals. Gene therapy, cellular reprogramming, and immune tolerance induction are active areas of research that may eventually deliver a true cure — but they remain in early investigational stages.

Understanding Remission: What It Looks Like and How Long It Lasts

If a cure means permanent elimination of psoriasis, remission means something more realistic and — for most patients — more immediately achievable: a period during which the skin is largely or completely clear, symptoms are absent or minimal, and quality of life is restored. For many people with psoriasis, sustained remission is indistinguishable from a cure in practical daily life terms.

PASI Scores: The Medical Standard for Psoriasis Clearance

Clinicians measure psoriasis severity and treatment response using the Psoriasis Area and Severity Index (PASI), which scores redness, thickness, and scaling across different body surface areas on a scale of 0 to 72. The clinical benchmarks for treatment success are:

•       PASI 75: 75% or greater reduction in PASI score from baseline — the traditional minimum benchmark for biologic therapy approval

•       PASI 90: 90% or greater reduction — the current standard for modern biologic efficacy assessment

•       PASI 100: 100% reduction — complete skin clearance, used increasingly as the target for IL-17 and IL-23 inhibitor therapies

 

With the most effective modern treatments — particularly IL-17 and IL-23 inhibitors — PASI 90 responses are achieved in 70–80% of patients, and PASI 100 responses in 40–60%. These are not temporary improvements; patients on appropriate biologic therapy commonly maintain these responses for years. In practical terms, this means completely clear skin for extended periods — an outcome that was genuinely unachievable twenty years ago.

Spontaneous Remission: When Psoriasis Clears Without Treatment

Spontaneous remission — clearance without active treatment — occurs in a subset of psoriasis patients, most commonly in those with guttate psoriasis following a triggering infection, or in patients whose disease was mild and driven primarily by a single environmental factor. Studies suggest that approximately 20–40% of psoriasis patients experience at least one extended period of spontaneous remission during their lifetime. Pregnancy is also associated with significant improvement or complete remission in many women — particularly in the second and third trimester — though postpartum flares are common when this protective effect lifts.

Treatment-Induced Remission: What the Data Shows

With modern systemic and biologic therapy, treatment-induced remission is achievable for the majority of moderate-to-severe psoriasis patients. Long-term extension studies of major biologic trials show that patients who achieve PASI 90 or PASI 100 responses at week 12 frequently maintain those responses for three to five years or longer on continuous treatment. Some patients who discontinue biologic therapy after achieving complete clearance maintain remission for months to years — a phenomenon called 'drug-free remission' that is particularly seen with certain IL-23 inhibitors.

Drug-free remission after biologic therapy is an area of active research. Preliminary data suggests that patients who achieve PASI 100 (complete clearance) and then discontinue their biologic may maintain that clearance for longer than patients who stopped at PASI 90 — suggesting that achieving complete rather than near-complete clearance before withdrawing treatment improves the chances of sustained remission. This finding is reshaping clinical targets toward PASI 100 as a realistic and worthwhile goal.

Every Treatment Option for Psoriasis in India: An Honest Assessment

India's psoriasis patients have access to a broad treatment landscape — from basic topicals to cutting-edge biologics — but access is unequal, costs are significant, and many patients are undertreated relative to their disease severity. What follows is an honest assessment of each treatment category, including its realistic potential for remission, its limitations, and its place in the overall management strategy.

Topical Treatments: First Line for Mild to Moderate Disease

Topical treatments — creams, ointments, gels, and shampoos applied directly to the skin — are the starting point for most psoriasis management and the mainstay of mild-to-moderate disease. They do not produce remission in the sense of full clearance, but they can control symptoms effectively in patches and prevent progression.

Topical corticosteroids: The most widely prescribed topical in India. Effective for rapid symptom control — reducing redness, itch, and scaling within days. However, they do not address the underlying immune mechanism and cannot produce sustained clearance. Long-term continuous use causes skin thinning, stretch marks, and rebound flares on discontinuation. They are best used in rotational strategies under dermatologist supervision, not as a permanent daily treatment.

Vitamin D analogues (calcipotriol, calcitriol): Slow skin cell proliferation and have anti-inflammatory properties without the atrophy risk of steroids. Often combined with topical steroids (calcipotriol/betamethasone combination products are widely available) to enhance efficacy and reduce steroid load. Effective for long-term maintenance in mild disease.

Coal tar preparations: One of the oldest effective treatments — reduces scaling, itch, and inflammation, particularly on the scalp. The strong smell and staining limit adherence, but coal tar shampoos remain clinically valuable for scalp psoriasis. Not a remission-inducing treatment but a useful maintenance and adjunct tool.

Steroid-free plant-based topicals: A growing and increasingly evidence-backed category. Formulations containing curcumin, neem, bakuchi, aloe vera, and other botanicals target inflammation through multiple pathways — inhibiting NF-kB, suppressing pro-inflammatory cytokines, and slowing keratinocyte proliferation — without the rebound risk of steroids. For mild-to-moderate psoriasis, well-formulated botanical topicals offer a safe, sustainable daily management option with no dose ceiling and no risk of withdrawal flares.

Phototherapy: Highly Effective, Access-Limited

Phototherapy — particularly narrowband UVB (NB-UVB) — is one of the most effective non-systemic treatments for psoriasis and can produce extended remission periods after a course of treatment. It works by inducing apoptosis (programmed death) of overactivated T-cells in psoriatic plaques, reducing inflammatory cytokine production, and promoting regulatory T-cell activity. A standard course of 20–30 sessions (three times per week) produces significant improvement in 70–80% of patients, with some achieving complete clearance.

The primary limitation of phototherapy in India is access. NB-UVB units are concentrated in larger cities and major hospitals — patients in rural and semi-urban areas have little or no access. For those with access, phototherapy offers an excellent bridge to longer-term management, and can be combined with topical or systemic treatments to enhance efficacy. Remission after a phototherapy course typically lasts 3–12 months, after which maintenance therapy or repeat courses are needed.

Systemic Treatments: For Moderate to Severe Disease

Oral systemic treatments are used when psoriasis affects more than 10% of body surface area, significantly impairs quality of life, or fails to respond to topical and phototherapy approaches. All require medical supervision and regular blood test monitoring.

Methotrexate: The most widely used systemic treatment for psoriasis in India, primarily because of its low cost and wide availability. Effective in 50–60% of patients and can produce extended remission periods. The main limitations are liver toxicity with prolonged use, teratogenicity (must be avoided in pregnancy), and the requirement for regular liver function monitoring. For many Indian patients, methotrexate remains the most accessible effective systemic option.

Cyclosporine: Rapid-acting — often producing significant improvement within 4–6 weeks, making it valuable for severe flares and erythrodermic psoriasis. Limited to short courses (maximum 2 years) due to nephrotoxicity (kidney damage) and hypertension risk. Best used as rescue therapy rather than long-term management.

Acitretin: An oral retinoid particularly effective for pustular and erythrodermic psoriasis and for keratoderma (thick skin on palms and soles). Significant teratogenicity — strictly contraindicated in women of childbearing age, with a mandatory contraception requirement for up to 3 years after stopping. Useful in the right patient profile.

Apremilast (Otezla): A newer oral PDE4 inhibitor with a more favourable side effect profile than traditional systemics — no requirement for blood monitoring for liver or kidney function, no immunosuppression-related infection risk. Moderately effective (PASI 75 in approximately 30–40% of patients at 16 weeks). An option for patients who cannot tolerate traditional systemics or are not yet candidates for biologics.

Biologic Therapies: The Closest to Remission Currently Available

Biologic therapies represent the most significant advance in psoriasis treatment in the last three decades. These precision-engineered antibodies target the specific cytokines driving psoriatic inflammation — TNF-alpha, IL-17, and IL-23 — and produce levels of skin clearance previously impossible with any other treatment class.

TNF-alpha inhibitors (adalimumab, etanercept, infliximab): First-generation biologics with strong long-term safety data. PASI 75 in 60–70% of patients. Require TB screening before initiation — important in India where latent TB is common. Available in biosimilar forms that have reduced cost in recent years.

IL-17 inhibitors (secukinumab, ixekizumab): Second-generation biologics with superior efficacy — PASI 90 in 70–80% and PASI 100 in 40–55% of patients. Secukinumab (Cosentyx) is widely used in India and is available through some insurance schemes. IL-17 inhibitors are associated with slightly increased risk of candidal (fungal) infections and should be used cautiously in patients with inflammatory bowel disease.

IL-23 inhibitors (guselkumab, risankizumab): The newest and most targeted biologic class. Exceptional efficacy (PASI 90 in 80–85%, PASI 100 in 55–65%) with a dosing schedule as infrequent as once every 12 weeks after the initial loading phase — meaning just four injections per year for maintenance. IL-23 inhibitors are associated with the highest rates of drug-free remission after discontinuation of any biologic class currently available. They represent the current frontier of psoriasis pharmacotherapy.

The cost barrier in India: The primary obstacle to biologic access in India is cost. Without insurance coverage, biologic therapy for psoriasis costs between INR 50,000 and INR 2,00,000 per month depending on the specific medication and dosing. Patient assistance programmes from pharmaceutical manufacturers, some state government insurance schemes, and the availability of biosimilar versions of first-generation biologics have improved affordability for some patients — but biologics remain financially inaccessible for the majority of India's psoriasis patients.

Ayurvedic and Natural Approaches: What They Can and Cannot Do

Ayurveda's approach to psoriasis (described in ancient texts as Kitibha Kushta — a Vata-Kapha imbalance affecting the skin) has been practised for over 3,000 years on the Indian subcontinent. Modern pharmacological research has validated the mechanisms of several key Ayurvedic herbs and therapies, and the evidence base for their role in psoriasis management — while not yet at the level of biologic RCT evidence — is genuinely meaningful.

What Ayurvedic and Plant-Based Treatments Can Achieve

For mild to moderate psoriasis, well-formulated plant-based treatments can achieve sustained symptom control, reduce flare frequency, and — in some patients — maintain near-complete clearance as part of a comprehensive management strategy. This is not a marketing claim; it reflects the documented pharmacological activity of specific plant compounds that are increasingly supported by peer-reviewed research.

Curcumin (turmeric): Inhibits NF-kB — the transcription factor that drives overexpression of TNF-alpha, IL-6, and IL-8. Multiple controlled studies have demonstrated significant reductions in psoriasis severity scores with topical and oral curcumin. A 2015 study in BioMed Research International found that topical curcumin produced clinically meaningful improvements in PASI scores in mild-to-moderate psoriasis patients.

Bakuchi (Psoralea corylifolia): Contains psoralen compounds that — combined with natural or artificial UV exposure — inhibit DNA synthesis in rapidly proliferating keratinocytes. This is the same mechanism as pharmaceutical PUVA therapy. Bakuchi-based formulations have been used in Ayurvedic psoriasis treatment for centuries and are now supported by pharmacological evidence.

Neem (Azadirachta indica): Active compounds nimbidin and nimbolide suppress TNF-alpha and other pro-inflammatory cytokines through multiple immune pathways. Neem also has antibacterial and antifungal properties that protect against secondary infections in broken psoriatic skin.

Panchakarma therapy: A structured Ayurvedic detoxification programme involving Virechana (therapeutic purgation) and other purification procedures. A 2016 study published in Ancient Science of Life found clinically significant PASI score reductions following Panchakarma treatment in psoriasis patients. The proposed mechanism involves the reduction of systemic 'ama' (toxin accumulation) that perpetuates immune dysregulation.

What Ayurvedic Treatments Cannot Do

Honesty requires stating clearly that no Ayurvedic treatment has been demonstrated in large, rigorous, randomised controlled trials to produce the levels of skin clearance achievable with modern biologic therapy. For severe psoriasis — covering large body surface areas, affecting joints, or significantly impairing quality of life — Ayurvedic treatment alone is insufficient, and conventional medical treatment should be the primary approach. Claims that Ayurveda 'cures' psoriasis permanently are not supported by evidence and should be treated with the same scepticism as similar claims from any other treatment modality.

The value of Ayurvedic and plant-based approaches is greatest as part of an integrative strategy — complementing conventional medical treatment for moderate disease, providing a safe daily topical option that avoids steroid side effects, and addressing the systemic lifestyle factors (diet, stress, gut health) that influence psoriasis severity. This integrative approach — the best of evidence-based dermatology combined with evidence-backed natural medicine — is increasingly recognised by dermatologists as the optimal management framework for long-term psoriasis care.

Lifestyle Changes That Drive Remission

Every effective psoriasis treatment works through the immune system — and the immune system is profoundly responsive to lifestyle. The growing evidence base for lifestyle modification in psoriasis is not merely about 'wellness' — it reflects real, measurable effects on the cytokine networks, genetic expression patterns, and trigger environments that determine disease activity. These are not alternatives to medical treatment; they are evidence-backed complements that dramatically improve its outcomes.

Weight Management

Of all lifestyle interventions studied in psoriasis, weight loss in overweight and obese patients produces the most dramatic documented effects. Clinical trials — including randomised controlled trials — have demonstrated that weight loss of 10–15% of body weight produces PASI score reductions of 40–50% in obese psoriasis patients, independent of any medication change. One landmark Italian study found that in overweight psoriasis patients, 20 weeks of caloric restriction produced greater PASI improvements than adding a second medication. Adipose (fat) tissue produces pro-inflammatory cytokines including leptin, resistin, and TNF-alpha — the same cytokines that drive psoriatic plaques — meaning weight loss directly reduces the biological substrate of psoriatic inflammation.

Stress Management

Psychological stress activates the hypothalamic-pituitary-adrenal (HPA) axis and sympathetic nervous system, releasing cortisol and catecholamines that alter immune regulation in favour of the Th1 and Th17 pathways central to psoriasis. Conversely, effective stress management has documented anti-inflammatory effects. A randomised controlled trial by Fortune et al. found that psoriasis patients who received mindfulness-based cognitive therapy alongside phototherapy achieved clearance significantly faster than those receiving phototherapy alone — and maintained it longer. For a condition where psychological stress is the most commonly reported trigger, stress management is not optional adjunct care — it is a primary therapeutic strategy.

Dietary Modification

An anti-inflammatory diet — rich in omega-3 fatty acids (oily fish, flaxseed, walnuts), fresh vegetables, fruits, legumes, and whole grains, and low in refined carbohydrates, processed foods, red meat, and alcohol — is associated with measurably lower psoriasis severity scores in multiple observational and interventional studies. For Indian patients specifically, incorporating turmeric-rich cooking, consuming amla (Indian gooseberry, one of the richest vitamin C sources in the world), increasing leafy greens and oily fish consumption, and reducing high-glycaemic-index foods can produce meaningful improvements in inflammatory burden.

Smoking Cessation and Alcohol Reduction

Both smoking and heavy alcohol consumption promote systemic inflammation through epigenetic and immunological mechanisms that amplify the same pathways driving psoriasis. Quitting smoking is associated with progressive psoriasis improvement over 12–24 months and is particularly impactful for palmoplantar pustulosis, where smoking is considered a near-essential cofactor. Reducing alcohol consumption improves psoriasis control, reduces the risk of liver toxicity in patients on methotrexate, and removes a direct inflammatory trigger. These are among the highest-impact lifestyle changes any psoriasis patient can make — and their effects are additional to, not substituting for, medical treatment.

Gut Health Optimisation

The gut microbiome — the community of microorganisms in the intestine — influences systemic immune responses through multiple pathways, including the Th17/Treg balance central to psoriasis. People with psoriasis consistently show reduced gut microbiome diversity and altered microbial composition compared to healthy controls. Dietary interventions that support microbiome diversity — increasing fibre intake, consuming fermented foods, reducing antibiotic use, limiting processed foods and refined sugar — may reduce the systemic immune triggers that perpetuate psoriasis between flares. This is an active research area, but the preliminary evidence is consistent with the traditional Ayurvedic emphasis on gut health as foundational to skin health.

The Research Frontier: What Might Eventually Cure Psoriasis

The pace of psoriasis research has accelerated significantly over the last decade, driven by a deeper molecular understanding of the disease and by technological advances including gene editing, cellular immunotherapy, and the precision medicine revolution. While no cure is imminent, the scientific landscape suggests that the answer to 'can psoriasis be cured?' may eventually change.

Regulatory T-Cell Therapy: Reprogramming Immune Tolerance

One of the most promising research directions involves regulatory T-cells (Tregs) — the immune system's peacekeepers that prevent inflammatory responses from attacking healthy tissue. In psoriasis, Treg function is suppressed relative to the overactive Th17 response. Cellular therapy approaches that expand and reinforce Treg populations — similar in concept to the cellular immunotherapies now used in oncology — are being explored in experimental models. The goal is to restore immune tolerance to skin proteins, potentially producing durable remission without the need for ongoing drug therapy.

Gene Therapy and CRISPR

The identification of specific gene variants associated with psoriasis has raised the theoretical possibility of gene-level intervention. CRISPR-Cas9 gene editing technology — which can precisely modify specific DNA sequences — has been used experimentally to correct immune gene variants in laboratory and animal models. The practical, ethical, and safety challenges of applying gene editing to immune cells in living humans are substantial, and this approach remains in early research stages. However, the fundamental biological possibility of correcting psoriasis-associated genetic variants exists, and research is progressing.

The IL-23/Th17 Axis and Drug-Free Remission

The most near-term advance in psoriasis 'cure research' comes not from gene editing but from increasingly deep blockade of the IL-23/Th17 axis. Long-term extension data for guselkumab and risankizumab (IL-23 inhibitors) show that some patients who achieve PASI 100 and then discontinue treatment maintain complete clearance for 12, 24, or even 36 months — a form of drug-free remission that is unprecedented in psoriasis history. Ongoing trials are investigating whether achieving complete immune quiescence through intense early treatment can extend drug-free remission periods further, potentially toward a functional cure for some patients.

Microbiome-Targeted Interventions

As the role of the gut and skin microbiomes in psoriasis pathogenesis becomes clearer, therapeutic targeting of the microbiome is emerging as a potential treatment strategy. Faecal microbiota transplantation (FMT) — transferring gut bacteria from a healthy donor — has shown preliminary promise in small psoriasis studies. Targeted probiotic formulations designed to restore specific bacterial populations implicated in immune regulation are in clinical trial phases. While not a cure in current form, microbiome-targeted therapy may eventually reduce the immune trigger burden in psoriasis in ways that make long-term drug-free remission more achievable.

Living Well Without a Cure: A Practical Framework

Waiting for a cure that may be years or decades away is not a management strategy. The most useful framework for people with psoriasis today is one that maximises current quality of life through evidence-based treatment, lifestyle optimisation, and proactive trigger management — while remaining informed about how rapidly the treatment landscape is evolving.

The Three Pillars of Effective Psoriasis Management

Pillar 1 — Medical treatment matched to disease severity: Mild disease warrants topical treatment (steroid-free botanical topicals for long-term use, rotational steroids for acute flares, vitamin D analogues for maintenance). Moderate disease warrants phototherapy and/or systemic therapy. Severe disease warrants biologic therapy. Undertreating psoriasis — using only topicals for severe disease, for example — is one of the most common and consequential management errors in India, where access and cost pressures push patients toward inadequate treatment.

Pillar 2 — Lifestyle and trigger management: Weight control, stress management, smoking cessation, alcohol reduction, dietary modification, gut health optimisation, and sun exposure management each contribute measurably to disease control and are entirely within patient agency. Taken together, these lifestyle pillars can shift disease from moderate-active to mild-controlled, or from mild-controlled to remission.

Pillar 3 — Psychological and social wellbeing: The psychological burden of psoriasis — depression, anxiety, social withdrawal, relationship difficulties — requires proactive attention alongside physical treatment. Connecting with peer support, seeking mental health care when needed, educating family and community members, and working with a dermatologist who understands the full impact of the condition are all part of comprehensive psoriasis management.

When to See a Dermatologist and How Often

Anyone with psoriasis affecting more than a small area of skin, causing significant discomfort or emotional distress, affecting the joints, face, scalp, genitals, or nails, or failing to respond to over-the-counter treatments should be under the care of a dermatologist rather than managing independently. Dermatological review every 3–6 months is appropriate for most patients on systemic or biologic therapy — and more frequently during flares or when changing treatment. Early specialist involvement is consistently associated with better long-term outcomes.

Conclusion: No Cure Yet — But Remarkable Control Is Possible Today

Can psoriasis be cured? Not yet — and intellectual honesty requires saying so clearly, without offering false hope in place of accurate information. Psoriasis is a chronic autoimmune condition rooted in genetic programming and immune system behaviour that no currently available treatment can permanently eliminate. The patches may clear, the itch may stop, the skin may look and feel entirely normal for months or years — but the predisposition remains, waiting to be reactivated if the right triggers arrive.

And yet, the full picture is considerably more hopeful than that single fact suggests. Modern biologic therapy produces complete skin clearance in the majority of treated patients and sustains it for years. Drug-free remission of a year or more is achievable after certain treatments. Lifestyle changes — particularly weight management, stress reduction, and dietary modification — produce measurable reductions in disease activity independently of medication. And at the research frontier, immune tolerance therapy, gene editing, and microbiome-targeted interventions offer genuine scientific pathways toward what would, in functional terms, be a cure. The honest answer to the question 'can psoriasis be cured?' is: not yet — but the gap between 'managed' and 'cured' has never been narrower.

Frequently Asked Questions: Can Psoriasis Be Cured?

Q1. Is there any treatment that permanently cures psoriasis?

No treatment currently available permanently cures psoriasis. All existing treatments — from topical creams to the most advanced biologic injections — manage the disease by suppressing or interrupting the immune mechanism that drives it. When treatment is stopped, psoriasis typically returns, though the interval before return varies widely depending on the treatment used and the individual's disease profile. Drug-free remission of 12 months or more is documented with some IL-23 inhibitors after complete clearance, but this is not yet a reliable permanent cure.

Q2. Can psoriasis go away on its own?

Yes — spontaneous remission occurs in a meaningful proportion of psoriasis patients, most commonly in those with guttate psoriasis following a triggering infection, and in pregnant women in the second and third trimester. Studies suggest 20–40% of psoriasis patients experience at least one extended period of spontaneous remission. However, this does not mean the genetic predisposition has gone — psoriasis typically returns when triggering factors re-emerge. Spontaneous remission is real but unpredictable, and it should not be counted on as a management strategy for moderate-to-severe disease.

Q3. What is the best treatment for psoriasis in India?

The best treatment depends entirely on disease severity and extent. For mild psoriasis, well-formulated topicals — including steroid-free plant-based options — plus lifestyle management is appropriate. For moderate disease, phototherapy (NB-UVB) and/or systemic therapy (methotrexate, apremilast) are the standard approach. For severe psoriasis, biologic therapy — particularly IL-17 or IL-23 inhibitors — offers the highest chance of near-complete or complete clearance. A dermatologist is the essential guide for matching treatment to disease severity.

Q4. Can Ayurvedic treatment cure psoriasis permanently?

No Ayurvedic treatment has been demonstrated in large-scale clinical trials to permanently cure psoriasis. However, well-formulated Ayurvedic topicals and systemic herbs can produce meaningful, sustained improvement in mild-to-moderate psoriasis, reduce flare frequency, and provide a safe long-term topical alternative to steroids. Ayurvedic approaches are most valuable as part of an integrative management strategy alongside appropriate conventional medical care — not as a standalone alternative for moderate-to-severe disease. Claims of permanent cure from any single treatment should be treated with scepticism.

Q5. How long does psoriasis remission last?

Remission duration varies enormously between patients and treatment approaches. Spontaneous remission can last from months to years and is unpredictable. After a phototherapy course, remission typically lasts 3–12 months. After stopping systemic treatments, flares typically return within weeks to months. The most durable remissions are seen with IL-23 inhibitors, where drug-free remission of 12–36 months has been documented in patients who achieved complete clearance before stopping treatment. No treatment guarantees a specific remission duration.

Q6. Does psoriasis get worse with age?

Psoriasis does not inevitably worsen with age, but its course is influenced by cumulative lifestyle factors that often change over time. Weight gain, accumulated chronic stress, hormonal changes at menopause, increasing comorbidities, and decades of suboptimal treatment can all contribute to worsening disease severity over time. Conversely, patients who actively manage their weight, lifestyle, and treatment tend to find that their disease becomes more stable and controllable with age, as they gain knowledge of their triggers and develop effective management routines.

Q7. Can stress cause a psoriasis cure to stop working?

Yes — psychological stress can directly reduce the effectiveness of psoriasis treatments by activating the same immune pathways that treatments are designed to suppress. Stress elevates cortisol and catecholamines that promote Th1 and Th17 immune responses, potentially overwhelming even effective treatment. Patients who experience a treatment 'stopping working' after a period of significant life stress — bereavement, job loss, relationship breakdown — should mention this to their dermatologist, as adding stress management to their care plan may restore treatment efficacy without requiring a medication change.

Q8. Are biologics the closest thing to a cure currently available?

In practical terms, yes — particularly IL-23 inhibitors, which can produce complete skin clearance (PASI 100) in 55–65% of patients and maintain it for years on continuous treatment. Some patients who stop IL-23 inhibitor therapy after achieving PASI 100 maintain drug-free remission for 12 months or more — an outcome that is the closest thing to a functional cure available today. The primary barriers to biologic therapy in India are cost and access rather than efficacy.

Q9. Will a cure for psoriasis be found in my lifetime?

This is a genuinely open question that depends on both scientific progress and the individual's age. The pace of psoriasis research has accelerated dramatically — the molecular targets driving the disease are now understood in granular detail, gene editing technologies are advancing rapidly, and immune tolerance therapies are entering clinical development. Many leading psoriasis researchers believe that sustained drug-free remission — essentially a functional cure — will be achievable for a significant proportion of patients within 10–20 years. A complete cure eliminating genetic predisposition remains more distant, but it is a scientifically plausible goal rather than a fantasy.

Q10. What can I do today to maximise my chances of remission?

The most evidence-based steps you can take immediately are: see a dermatologist and ensure your treatment is appropriate for your disease severity (undertreating psoriasis is common and delays remission); achieve and maintain a healthy weight; quit smoking if you smoke; reduce alcohol to minimal or nil; manage stress through daily practice — yoga, meditation, or exercise; follow an anti-inflammatory diet rich in omega-3 fatty acids and fresh vegetables; treat infections promptly; and use a steroid-free topical for daily skin maintenance rather than repeated courses of potent steroids. Together, these steps measurably shift the balance toward remission.

Sources and References

•       Griffiths CEM, Armstrong AW, Gudjonsson JE, Barker JNWN. Psoriasis. Lancet. 2021;397(10281):1301–1315.

•       Boehncke WH, Schön MP. Psoriasis. Lancet. 2015;386(9997):983–994.

•       Menter A, et al. Joint AAD-NPF guidelines of care for the management of psoriasis with biologics. J Am Acad Dermatol. 2019;80(4):1029–1072.

•       Lowes MA, Suárez-Fariñas M, Krueger JG. Immunology of psoriasis. Annu Rev Immunol. 2014;32:227–255.

•       Nestle FO, Kaplan DH, Barker J. Psoriasis. N Engl J Med. 2009;361(5):496–509.

•       Gordon KB, et al. Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2). Lancet. 2018;392(10148):650–661.

•       Blauvelt A, et al. Secukinumab administration by autoinjector maintains sustained efficacy in plaque psoriasis. Br J Dermatol. 2015;172(2):484–493.

•       Bachelez H, et al. Long-term remission with guselkumab in patients with moderate-to-severe plaque psoriasis. NEJM Evid. 2022.

•       Fortune DG, et al. Psychological distress impairs clearance of psoriasis in patients treated with phototherapy. Arch Dermatol. 2003;139(6):752–756.

•       Naldi L, et al. Cigarette smoking, body mass index, and stressful life events as risk factors for psoriasis. J Invest Dermatol. 2005;125(1):61–67.

•       Budu-Aggrey A, et al. Evidence of a causal relationship between body mass index and psoriasis. PLOS Med. 2019;16(1):e1002739.

•       Scher JU, Abramson SB. The microbiome and psoriatic disease. J Invest Dermatol. 2011;131(12):2442–2444.

•       Dogra S, Mahajan R. Psoriasis: epidemiology, clinical features, co-morbidities. Indian Dermatol Online J. 2016;7(6):471–480.

•       Chandra Shekhar M, et al. Evaluation of Panchakarma therapy in psoriasis. Ancient Science of Life. 2016;35(3):159–164.

•       Chouela E, et al. Curcumin and psoriasis. BioMed Research International. 2015. doi:10.1155/2015/619168.

•       Armstrong AW, et al. Psoriasis and the risk of diabetes mellitus. JAMA Dermatol. 2013;149(1):84–91.

•       Thawani M, et al. Cost of illness of psoriasis in India. Indian J Dermatol. 2019;64(5):390–396.

•       National Psoriasis Foundation. About Psoriasis. www.psoriasis.org (accessed 2024).

•       World Health Organization. Global Report on Psoriasis. Geneva: WHO; 2016.

•       IADVL Psoriasis Task Force. Indian guidelines for the management of psoriasis. Indian J Dermatol Venereol Leprol. 2020.

 

Last reviewed: June 2026. This article is for informational purposes only and does not substitute for professional medical advice. Always consult a qualified dermatologist for diagnosis and personalised treatment.